Abstract
Background Conventional wisdom wrongly holds that the microbiological of M. tuberculosis complex in clinical specimens via culture and phenotypic drug susceptibility testing allows people to be correctly diagnosed and ensures an effective treatment regimen to be selected. This study was aimed to characterize first-and second-line anti-tuberculosis drug resistance profiles among new pulmonary tuberculosis cases in Addis Ababa metropolitan area, Ethiopia.
Methods A prospective cross-sectional study was conducted between October 2019 and June 2021 among bacteriologically confirmed new presumptive pulmonary tuberculosis cases. GeneXpert MTB/RIF Assay was utilized for initial testing and early detection of rifampicin resistance. Mycobacterial culture and drug susceptibility testing were performed against FOUR first-line and ELEVEN second-line anti-TB drugs using BD BACTEC™ MGIT™ 960 automated liquid culture system.
Results A total of 156 M. tuberculosis complex isolates were successfully recovered using BD BACTEC™ MGIT™ 960 automated liquid culture system and were subjected to drug susceptibility testing. Males account for 53.8 % (84/156). The median age of the study participants was 30.0 years. Of all the study participants, 58.3 % (91/156) were married, and 76.9% (120/156) were urban residents. Overall, we identified 14.1% (22/156) resistance to at least one anti-TB drug and 85.9% (134/156) pan-susceptible M. tuberculosis strains. Further, 7.1% (11/156) of isolates were monoresistant, 5.8% (9/156) of isolates were MDR-TB strains, and 3.8% (6/156) of isolates were resistant to all first-line anti-TB drug regimens. Interestingly, all isolates were susceptible to all recently recommended second-line anti-TB drugs, and none of these isolates were found to be pre-XDR or XDR-TB. The rate of RR-TB detected was 10.9% (17/156) and 5.8% (9/156) using GeneXpert MTB/RIF Assay and BD BACTEC™ MGIT™ 960 SIRE liquid culture system, respectively. The sensitivity, specificity, PPV, NPV, accuracy, and Kappa value were 100%, 94.6%, 52.9%, 100%, 94.9%, and 0.667, respectively.
Conclusion The rate of MDR-TB in new pulmonary TB cases remained high at fivefold the national and nearly twofold the global estimated rate. The rate of monoresistance against anti-TB drugs was also high. The absence of resistance against recommended second-line anti-TB drugs was quite encouraging. However, the high rate of resistance against Ethionamide would mean that its inclusion in the regimens may not have therapeutic benefit in this geographic area. Furthermore, the low specificity of GeneXpert MTB/RIF Assay might introduce a significant rate of (47.1%; 8/17) false rifampicin resistance leading the patient to erroneous MDR-TB category and placing on an unnecessary second-line anti-TB-treatment regimen. Enhanced efforts are required to progressively validate and harmonize rapid molecular diagnostics against reference methods to address the diagnosis challenges and improve patient outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study protocol was approved by the Institutional Review Board of the Department of Microbial, Cellular and Molecular Biology, College of Natural and Computational Sciences, Addis Ababa University on April 04, 2019, and Protocol No. IRB.039.2019. An official permission letter before the commencement of the study was also obtained from Saint Peter TB Specialized Hospital. Written informed consent was obtained from each study subject and guardian. Data were delinked from the source file, avoided study subject identifiers, and analyzed in aggregates to ensure confidentiality and anonymity.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* Email: gtakalu{at}gmail.com (GTA)
Data Availability
All relevant data are within the manuscript and its Supporting Information files.
